Biodel Prices Public Offering of Common Stock
DANBURY, Conn., June 19, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD)
today announced the pricing of an underwritten public offering of 4,482,760
shares of its common stock at a public offering price of $4.35 per share. All
of the shares are being sold by Biodel. The offering is expected to close on
June 24, 2013, subject to customary closing conditions. Biodel has also
granted the underwriters a 30-day option to purchase up to an additional
672,414 shares to cover overallotments, if any.
William Blair & Company, L.L.C. is acting as the sole book-running manager of
the offering and Ladenburg Thalmann & Co. Inc. is acting as co-manager for the
The shares will be issued pursuant to a shelf registration statement on Form
S-3 previously filed and declared effective by the Securities and Exchange
Commission. Biodel will also file with the Securities and Exchange Commission
a prospectus supplement with respect to the offering.
This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy any securities of Biodel, nor shall there be any offer or sale
of securities in any state or jurisdiction in which an offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any offer will be made only
by means of a prospectus supplement and accompanying prospectus forming a part
of the effective registration statement, copies of which may be obtained, when
available, from William Blair & Company, L.L.C. at 222 West Adams Street,
Chicago, IL 60606, Attention: Prospectus Department, by telephone at (800)
621-0687, or by email at firstname.lastname@example.org.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for diabetes that
may be safer, more effective and more convenient for patients. Biodel Inc.
develops its product candidates by applying its proprietary formulation
technologies to existing drugs in order to improve their therapeutic profiles.
CONTACT: Seth D. Lewis, +1-646-378-2952
Press spacebar to pause and continue. Press esc to stop.